<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04033341</url>
  </required_header>
  <id_info>
    <org_study_id>17199</org_study_id>
    <secondary_id>I8S-MC-JUAD</secondary_id>
    <nct_id>NCT04033341</nct_id>
  </id_info>
  <brief_title>A Study of LY3214996 in Healthy Participants</brief_title>
  <official_title>Disposition of [14C]-LY3214996 Following Oral Administration in Healthy Male Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eli Lilly and Company</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main purpose of this study is to measure how much of the study drug gets into the
      bloodstream and how long it takes the body to get rid of it. This study will involve a single
      dose of 14C radiolabelled LY3214996. This means that a radioactive substance, C14, will be
      incorporated into the study drug. The purposes are to investigate the study drug and its
      breakdown products and to find out how much of these pass from blood into urine and feces.
      The study will last up to six weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2019</start_date>
  <completion_date type="Actual">September 9, 2019</completion_date>
  <primary_completion_date type="Actual">September 9, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Urinary Excretion of LY3214996 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Baseline through Day 8 after administration of study drug</time_frame>
    <description>Urinary Excretion of LY3214996 Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Fecal Excretion of LY3214996 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered</measure>
    <time_frame>Baseline through Day 8 after administration of study drug</time_frame>
    <description>Fecal Excretion of LY3214996 Radioactivity Over Time Expressed As A Percentage of the Total Radioactive Dose Administered</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY3214996</measure>
    <time_frame>Predose through Day 8 after administration of study drug</time_frame>
    <description>PK: Cmax of LY3214996</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PK: Area Under the Concentration Time Curve From Time Zero to Infinity (AUC[0-∞]) of LY3214996</measure>
    <time_frame>Predose through Day 8 after administration of study drug</time_frame>
    <description>PK: AUC(0-∞) of LY3214996</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Metabolites of LY3214996</measure>
    <time_frame>Baseline through 48 hours after administration of study drug</time_frame>
    <description>Total Number of Metabolites of LY3214996</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>LY3214996 + [14C]-LY3214996</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A single dose of LY3214996 and [14C]-LY3214996 administered orally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LY3214996</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3214996 + [14C]-LY3214996</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>[14C]-LY3214996</intervention_name>
    <description>Administered orally</description>
    <arm_group_label>LY3214996 + [14C]-LY3214996</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Overtly health males

          -  Body mass index (BMI) of 18.0 to 32.0 kilograms per square meter (kg/m²), inclusive

        Exclusion Criteria:

          -  Females

          -  Male participants sexually active with a pregnant partner

          -  Are currently enrolled in a clinical study or have participated, within the last 30
             days, in a clinical study

          -  Have participated in a radiolabeled drug study within the previous 4 months

          -  Have a history or presence of cardiovascular, respiratory, hepatic, renal,
             gastrointestinal, endocrine, hematological, or neurological disorders

          -  Have a history of Gilbert's syndrome

          -  Have history or presence of psychiatric disorders

          -  Show evidence of human immunodeficiency virus (HIV) infection

          -  Show evidence of hepatitis C

          -  Show evidence of hepatitis B
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)</last_name>
    <role>Study Director</role>
    <affiliation>Eli Lilly and Company</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Covance Clinical Research Inc</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>July 24, 2019</study_first_submitted>
  <study_first_submitted_qc>July 24, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 26, 2019</study_first_posted>
  <last_update_submitted>October 26, 2019</last_update_submitted>
  <last_update_submitted_qc>October 26, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 29, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

